Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

Xiao-yuan Fan, Xin-lei Hu, Tie-mei Han, Na-na Wang, Yi-miao Zhu, Wen Hu, Zhen-hua Ma, Chen-jing Zhang, Xiang Xu, Zai-yuan Ye, Chun-mao Han and Wen-sheng Pan

Abstract

Background: Runt-related transcription factor 3 (RUNX3) is a member of the runt-domain family of transcription factors and has been reported to be a candidate tumor suppressor in gastric cancer. However, the association between RUNX3 promoter methylation and gastric cancer remains unclear.

Methods: We systematically reviewed studies of RUNX3 promoter methylation and gastric cancer published in English or Chinese from January 2000 to January 2011, and quantified the association between RUNX3 promoter methylation and gastric cancer using meta-analysis methods.

Results: A total of 1740 samples in 974 participants from seventeen studies were included in the meta-analysis. A significant association was observed between RUNX3 promoter methylation and gastric cancer, with an aggregated odds ratio (OR) of 5.63 (95%CI 3.15, 10.07). There was obvious heterogeneity among studies. Subgroup analyses (including by tissue origin, country and age), meta-regression were performed to determine the source of the heterogeneity. Meta-regression showed that the trend in ORs was inversely correlated with age. No publication bias was detected. The ORs for RUNX3 methylation in well-differentiated vs undifferentiated gastric cancers, and in intestinal-type vs diffuse-type carcinomas were 0.59 (95%CI: 0.30, 1.16) and 2.62 (95%CI: 1.33, 5.14), respectively. There were no significant differences in RUNX3 methylation in cancer tissues in relation to age, gender, TNM stage, invasion of tumors into blood vessel or lymphatic ducts, or tumor stage.

Conclusions: This meta-analysis identified a strong association between methylation of the RUNX3 promoter and gastric cancer, confirming the role of RUNX3 as a tumor suppressor gene.

Background

Gastric cancer is the second most common gastrointestinal tumor worldwide. Although its incidence continues to decline year by year, it remains the second most common cause of cancer-related deaths [1,2].

Runt-related transcription factor 3 (RUNX3) is a member of the runt domain family of transcription factors, also known as polymavirus enhancer-binding protein 2 (PEBP2)/core binding factors (CBF) [3-5]. RUNX3 is a known regulator of major developmental pathways, and has recently been reported as a candidate tumor suppressor [3-5]. RUNX3 is located on human chromosome region 1p36 and plays an important role in the transforming growth factor (TGF)-β signaling pathway. This may occur partly through interaction with FoxO3a/FKHRL1, both of which are indispensable for the activation of the pro-apoptosis protein Bim (Bcl-2-interacting mediator of cell death), or by cooperating with SMAD protein family members to induce the TGF-β/SMAD pathway in other ways [6,7]. The RUNX3 gene is regulated by three main mechanisms: loss of heterozygosity (LOH), protein mislocalization, and promoter methylation [3,5,8,9]. Silencing of the promoter region CpGs of regulated genes via hypermethylation is recognized as one of the mechanisms responsible for loss-of-gene-function in Knudson’s two-hit tumor progression hypothesis[10]. Numerous studies using cell lines, knockout animals, and primary human cancer samples have demonstrated a crucial role for RUNX3 not only in normal development, but also in neoplasias, especially stomach cancers [3,5,11]. Previous studies have reported...
the involvement of RUNX3 promoter methylation in many cancers, including colorectal [12,13], gastric [14], bladder [15], breast [16], lung [17], oral [18], and nasopharyngeal cancers [19]. However, the role of RUNX3 in the regulation of gastric epithelial cell growth and its tumor suppressor activity in gastric cancer remain to be clarified. Levanon and colleagues questioned the causal relationship between loss of RUNX3 expression and gastric cancer, and reported that RUNX3-deficient mice did not develop gastric hyperplasia or gastric tumors [20,21]. Carvalho et al. refuted a tumor suppressor role for the RUNX3 gene in early-onset gastric carcinomas, on the basis of its lack of expression in histological non-neoplastic gastric epithelium, although at least two copies of the gene were present in the vast majority of cells analyzed [22]. However, associations between RUNX3 promoter methylation and gastric cancer have mostly been investigated in studies with small sample sizes, low statistical power, specific ethnic backgrounds, or other limitations in study design, leading to conflicting results.

Meta-analysis is a well-established method for quantifying gene-disease associations more precisely, by using all the available published data to increase the statistical power [23]. We therefore conducted a meta-analysis using all available related studies to better define the association between RUNX3 promoter methylation and gastric cancer.

Methods
Search strategy
This pooled study involved searching a range of computerized databases, including Medline, Blackwell, Cochrane Central, Web of Science, and Ovid, for articles published in English or Chinese from January 2000 to January 2011. The study used a subject and text word strategy with (RUNX3 OR AML2 OR CBF3 OR PEBP) AND ((gastric OR stomach) AND (cancer OR neoplasm)) as the primary search terms. The search strategy was tailored to each database to ensure that the search was comprehensive and not limited to randomized controlled trials.

Selection of studies and data extraction
Three independent reviewers (Fan, Hu and Pan) screened the titles and abstracts identified by the electronic search to identify relevant studies. Relevant articles were further examined to see if they met the inclusion criteria. The reference sections of all retrieved articles were searched to identify further relevant articles. A citation search was carried out on all included articles using the Science Citation Index. Potentially relevant papers were obtained and the full text articles were screened for inclusion by two independent reviewers (Fan, Hu). Disagreements were resolved by discussion. Included studies were summarized in data extraction forms. Authors were contacted when relevant data were missing.

The name of the first author, year of publication, origin of the study patients, sample size, and methylation status of the RUNX3 promoter in human gastric cancer and normal or control tissues were extracted. The inclusion criteria were as follows: the patients had to be diagnosed with gastric cancer and the studies had to have RUNX3 gene promoter methylation data from tissue samples. The following types of studies were excluded: animal experiments, case reports, review articles or meta-analyses, and studies with insufficient data.

Data analysis and synthesis
Data were analyzed mainly using STATA Software (Stata/SE 11.0 for Windows, StataCorp LP). The strength of association was expressed as pooled odds ratio (OR) with corresponding 95% confidence intervals (CI). Data were extracted from the original studies and recalculated if necessary. The data were pooled using the DerSimonian and Laird random effects model [24], which takes account of both within-study and between-study variations. A two-sided \( P \leq 0.05 \) was considered significant. Heterogeneity was tested using the I² statistic with values >50% and \( \chi^2 \) test with \( P \leq 0.05 \) indicating strong heterogeneity between the studies. \( \tau^2 \) was used to determine how much heterogeneity was explained by subgroup differences [25]. If the heterogeneity was significant, Galbraith plot and meta-regression analyses were employed to analyze the sources of the heterogeneity. Subgroup analyses of the ORs of RUNX3 promoter methylation in cancer tissue versus normal tissue were performed according to control types (autogenous and heterogeneous), patient origins (Europe-America, China, Japan, and Korea) and age categories (<60, between 60 and 65, and ≥65). Sensitivity analyses were performed to assess the contributions of single studies to the final results. Possible bias was analyzed by funnel plot. If bias was suspected, the meta-trim method was used to re-estimate the effect size. Differences in methylation status of cancer tissues were also analyzed in relation to age (≥60, >60), gender (male, female), metastases, and pathological cancer type.

Results
Study characteristics
The electronic search strategy identified 132 potentially relevant articles, which were further screened for inclusion on the basis of their titles, abstracts, full texts, or a combination of these. The electronic search was supplemented from reference lists of relevant articles including reviews, and by discussion with experts.
A total of 55 full-text articles were retrieved, of which 38 were excluded. The remaining 17 studies included data on the relationship between RUNX3 gene promoter methylation and gastric cancer, and these studies were pooled for analysis (Table 1) [14,26-41]. Sixteen of the included articles were written in English, and one was written in Chinese. The main characteristics of each study are shown in the supplementary data (Table 1).

Among the 17 retrieved articles, 16 observations in 15 studies used methylation-specific polymerase chain reaction to explore RUNX3 promoter methylation in gastric cancer tissues (n = 928) and normal tissues (n = 812), with a total sample size of 1740 cases. The total number of participants is 974 from 17 articles including 890 patients from 17 articles and 84 controls from 3 articles which provided heterogeneous control groups. The pooled OR for RUNX3 methylation in cancer tissues compared with normal tissues was 5.63 (95%CI 3.15-10.06, z = 5.82, P < 0.0001), indicating an increased likelihood of methylation in gastric cancer tissue, compared with normal tissue (Figure 1).

Subgroup analysis and meta-regression

The OR in the autologous tissue subgroup was 6.42 (95% CI: 4.07, 10.11; P < 0.0001) and that in the heterogeneous tissue subgroup was 4.44 (95%CI: 0.35, 56.70; P = 0.251) (Table 2). Tissue subgroup analysis showed that the incidence of methylation in autologous cancer tissues was higher than that in normal tissues, but there was no obvious difference between autologous and heterogeneous tissues. The difference was not deemed significant by the random effects method, because of the existing heterogeneity (I² = 89.30%, $\chi^2 = 18.69$; P < 0.0001) (Table 2). The OR for the Japanese subgroup was 3.20 (95%CI: 1.60, 6.39; P = 0.001), for the European-American subgroup was 5.15 (95%CI: 0.23, 113.17; P = 0.251), for the Chinese subgroup was 26.19 (95%CI: 8.04, 85.33; P < 0.0001), and for the Korean subgroup was 4.96 (95%CI: 2.14, 11.47; P < 0.0001) (Table 2, Figure 1). Heterogeneity also existed within patients of each origin, especially in the European-American subgroup (I² = 83.20%, $\chi^2 = 5.95; P = 0.015$), which changed the OR from significant (fixed) to non-significant (random) (Table 2, Figure 1). The OR for the age <60 group was 15.00 (95%CI: 5.21, 43.15; P < 0.0001), that for the 60-65 subgroup was 6.31 (95%CI: 3.19, 12.46; P < 0.0001), and that for the ≥65 subgroup was 3.75 (95%CI: 1.29, 10.89; P = 0.015) (Table 2, Figure 1).

Heterogeneity existed in all studies (I² = 74.10%, $\chi^2 = 57.91; P < 0.0001$) (Table 2). We therefore performed further analyses using the meta-regression method with the Knapp-Hartung modification. The restricted maximum likelihood method was used to estimate between-study variance.

The results of meta-regression indicated that the trend in ORs was inversely correlated with age, which accounted for some of the heterogeneity (coefficient = -0.16, P = 0.042, adjusted $R^2 = 44.47$%, Table 3). However, other factors such as sample size, year of publication, proportion of males, and the origin of the patients could not explain the heterogeneity (Table 3).

Bias analysis and robust estimation of pooled OR

A funnel plot of methylation status of gastric cancer tissue versus normal tissue showed that four studies exceeded the 95% confidence limits (Figure 2). We also performed sensitivity analyses to determine the effects of omitting a single study on the overall effect; omission of a single study changed the overall OR from 5.15 (2.85, 9.29) to 6.09 (3.37, 11.0) using the random method, suggesting that there was no single sensitive study (Table 4). Trim and fill analysis was performed using the random effects model. The pooled OR was 4.67 (95%CI: 2.57, 8.49; P < 0.0001) indicating a positive association between RUNX3 methylation and gastric cancer.

Comparators in cancer tissue

There were no significant differences in RUNX3 methylation status in cancer tissue in relation to age, gender, TNM stage, invasion of tumors into blood vessels or lymphatic ducts, or tumor stage, or tumor metastases (Data not shown).

The overall results demonstrated that RUNX3 methylation was more frequent in intestinal-type, compared with diffuse-type gastric carcinomas (OR = 2.62, 95%CI: 1.33, 5.14). Undifferentiated gastric cancer also had a higher methylation OR than well-differentiated cancer tissue (OR = 0.59, 95%CI: 0.30, 1.16) (Data not shown).

Discussion

The role of the RUNX3 gene in gastric cancer is controversial [3,20,22,42,43]. Inactivation of the RUNX3 gene can be caused by LOH, promoter hypermethylation, or protein mislocalization. Methylation of the RUNX3 promoter is one of the most common aberrant methylation events in cancer [44]. We therefore performed a meta-analysis to quantify the association between RUNX3 promoter methylation and gastric cancer.

The overall OR for methylation status in gastric cancer versus normal gastric tissue was 5.63 (3.15, 10.07), using a random effects model on pooled data from 16 observations in 15 studies. Subgroup analysis showed an OR in the heterogeneous tissue-origin subgroup of 4.44 (0.35, 56.70), which was significant in the fixed, but not in the random effects model. This discrepancy may be a result of the smaller number of studies analyzed. The ORs also differed in subgroups with
### Table 1 Basic characteristics of the included studies

| Study/Country | Mean/median age (range) (years) | Gender (M/F) | Patients (M+/M-) | Control (M+/M-) | Methods | Primary Aim | Methylation site | RUNX3 Expression |
|---------------|--------------------------------|--------------|------------------|----------------|---------|-------------|------------------|-----------------|
| Waki et al (2003)[26]/Japan | 64.3 (0.7-89) | 68/25 | 42/51 | 7/68A 4/15H | MSP, RT-PCR | Clarify the physiological consequence of DAP-kinase and RUNX3 age-related methylation in gastric epithelia | CpG islands | + |
| Oshimo et al (2004)[14]/Japan | 68.8 (38-87) | 56/24 | 57/23 | 38/7H | MSP, qRT-PCR | Loss of RUNX3 expression by promoter hypermethylation in Gastric Carcinoma | CpG islands | + |
| Nakase et al (2005)[27]/Japan | 65.4 | 81/32 | 14/8 | 6/16A | MSP, qRT-PCR | Determine whether alteration of RUNX3 gene expression could be detected in the normal-looking gastric remnant mucosa stomach after distal gastrectomy for peptic ulcer or gastric cancer | promoter hypermethylation | + |
| Homma et al (2006)[28]/USA | 63 (30-85) | 28/17 | 43/2 | 43/2A | MSP | Clarify how methylation spreads within the CpG island | region NO.1 at CpG islands | - |
| So et al (2006)[29]/Japan | 64 (30-82) | 17/9 | 11/5 | 6/20A | MSP, microarray | Use microarray-based methylation assay to assess gene methylation | CpG islands | - |
| Mitsuno et al (2007)[30]/Japan | 63.2 (26-86) | 29/9 | 18/20 | Not reported | MSP | Determine whether DNA methylation in six cancer-related genes affects recurrence of gastric cancer in patients who received 5-fluorouracil-based adjuvant chemotherapy | CpG islands | - |
| Gargano et al (2007)[31]/Italy | Not reported | 65/35 | 22/18 | 2/38A | MSP | Investigate a possible relationship between the RUNX3 promoter methylation, nuclear microsatellite instability and mitochondrial microsatellite instability | CpG islands | - |
| Fujii et al (2008)[32]/Japan | 62.8 (52-77) | 8/9 | 11/6 | Not reported | MSP, CHIP, RT-PCR | Enhancer of Zeste Homologue 2 (Ezh2) down-regulates RUNX3 by increasing histone H3 methylation | CpG islands | + |
| Kitajima et al (2008)[33]/Japan | 65.71 | 34/23 | 30/27 | 10/47A | MSP, PCR | Determine the Helicobacter pylori infection as an independent risk factor for Runx3 methylation in gastric cancer | CpG islands | + |
| Li et al (2008)[34]/China | 62 (35-78) | 23/17 | 22/18 | 0/40A | MSP | Analyze the relationships among the aberrant methylation of RUNX3 gene promoter, the RUNX3 protein expression and clinicopathological features in gastric cancer | CpG islands | + |
| Song et al (2008)[35]/Korea | 64 | 50/29 | 26/53 | 9/70A | MSP | Determine the methylation of RUNX3 promoter and the association between RUNX3 methylation and the clinicopathological characteristics of patients with gastric carcinoma | CpG islands | - |
| KIM et al (2009)[36]/Republic of Korea | 57.7 | 53/21 | 18/56 | 2/61A | MSP | Comparison of DNA methylation between primary and metastatic gastric carcinoma | promoter | - |
| Zou et al (2009)[37]/China | 65.15 | 40/17 | 14/2 | 0/20H | MSP | Determine the methylation frequency of 5 genes, including p16, Runx3, MGMT, DAPK, and RASSF1A | CpG islands | + |
| Chen et al (2010)[38]/China | 53 (20-78) | 20/50 | 28/42 | 2/68A | MSP, RT-PCR | Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer | CpG islands | + |
| Hiraki et al (2010)[39]/Japan | 68.6 (45-88) | 30/19 | 28/21 | 14/35A | q-MS, qRT-PCR | Determine whether gene methylation is a novel diagnostic marker for micrometastasis to the lymph nodes (LNs) in gastric cancer | Promoter hypermethylation | + |
Table 1 Basic characteristics of the included studies (Continued)

| Study ID | Country | Age (Range) | Sex | Tumor Invaded | Methodology | Pathobiologic implications | CpG islands |
|----------|---------|-------------|-----|--------------|-------------|---------------------------|-------------|
| Hu et al (2010) [40]/China | 64.1 | 97/26 | 68/55 | 12/111A | MSP, RT-PCR | Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer | + |
| Mikata et al (2010) [41]/Japan | 70 (56-85) | 14/7 | 10/11 | 4/17A | MS, qRT-PCR, RT-PCR | BCL2L10 hypermethylation in gastric cancer and its correlation with RUNX3 | - |

A: Autologous control, the control tissues from the patients themselves; H: Heterogeneous control, the control tissues from other individuals. M+: The number of tissues with methylation; M-: The number of tissues with unmethylation.

| Study ID | Odds Ratio (95% CI) | Events, cancer (M+ or N) | Events, normal (M+ or N) | Weight |
|----------|----------------------|--------------------------|--------------------------|--------|
| Wakai (2003) | 10.12 (4.23, 24.20) | 42/93 | 7/83 | 7.73 |
| Wakai (2003) | 3.09 (0.95, 10.01) | 42/93 | 4/19 | 6.77 |
| Oshino (2004) | 0.46 (0.18, 1.17) | 57/80 | 38/45 | 7.52 |
| Nakase (2005) | 4.67 (1.30, 16.76) | 14/26 | 6/22 | 6.44 |
| So (2006) | 2.44 (0.74, 8.11) | 11/26 | 6/26 | 6.70 |
| Homma (2006) | 1.00 (0.13, 7.43) | 43/45 | 43/45 | 4.43 |
| Gargano (2007) | 23.22 (4.92, 109.87) | 22/40 | 2/40 | 5.61 |
| Li (2008) | 98.51 (5.56, 1713.15) | 22/40 | 0/40 | 2.67 |
| Krayna (2008) | 5.22 (2.21, 12.32) | 30/57 | 10/57 | 7.77 |
| Song (2008) | 3.82 (1.65, 8.82) | 26/79 | 9/79 | 7.84 |
| Kim (2009) | 9.80 (2.18, 44.17) | 18/74 | 2/83 | 5.75 |
| Zou (2009) | 237.80 (10.61, 5331.48) | 14/16 | 0/20 | 2.55 |
| Mikata (2010) | 3.86 (0.97, 15.44) | 10/21 | 4/21 | 6.11 |
| Chen (2010) | 22.67 (5.13, 100.09) | 28/70 | 2/70 | 5.61 |
| Hu (2010) | 11.44 (5.72, 22.88) | 68/123 | 12/123 | 8.26 |
| Hiraki (2010) | 3.33 (1.44, 7.72) | 28/49 | 14/49 | 7.83 |
| Overall (I-squared = 74.1%, p = 0.000) | 5.63 (3.15, 10.06) | 475/928 | 159/812 | 100.00 |

Subgroups:

| Subgroup | Odds Ratio (95% CI) | Events, cancer (M+ or N) | Events, normal (M+ or N) | Weight |
|----------|----------------------|--------------------------|--------------------------|--------|
| Euro-America | D+L Subtotal (I-squared = 83.2%, p = 0.015) | 5.15 (0.23, 113.17) | 65/85 | 45/85 | 10.04 |
| Japan | D+L Subtotal (I-squared = 72.0%, p = 0.001) | 3.20 (1.60, 6.39) | 234/441 | 89/332 | 56.88 |
| China | D+L Subtotal (I-squared = 48.4%, p = 0.121) | 26.19 (9.04, 85.33) | 132/249 | 14/253 | 19.49 |
| Korea | D+L Subtotal (I-squared = 15.5%, p = 0.277) | 4.96 (2.14, 11.47) | 44/153 | 11/142 | 13.59 |
| age=60 | D+L Subtotal (I-squared = 0.0%, p = 0.437) | 14.99 (5.21, 43.15) | 46/144 | 4/133 | 11.56 |
| age>60-85 | D+L Subtotal (I-squared = 62.9%, p = 0.009) | 6.31 (3.19, 12.46) | 270/539 | 83/465 | 50.21 |
| age>85 | D+L Subtotal (I-squared = 80.1%, p = 0.000) | 3.75 (1.29, 10.89) | 153/245 | 72/214 | 38.23 |

NOTE: Weights are from random effects analysis.

Figure 1 Forest plot of RUNX3 promoter methylation in cancer tissue vs normal tissue and subgroup analyses.
different ethnic origins: the OR in the Chinese subgroup was 26.19 (95%CI: 8.04, 85.33), followed by the European-American subgroup (OR = 5.15, 95%CI: 0.23, 113.17), the Korean subgroup (OR = 4.96, 95%CI: 2.14, 11.47), and the Japanese subgroup (OR = 3.20, 95%CI: 1.60, 6.39). The ORs for the different age subgroups were 15.00 (95%CI: 5.21, 43.15) for age <60, 6.31 (95%CI: 3.19, 12.46) for age 60-65, and 3.75 (95%CI: 1.29, 10.89) for age ≥65. Heterogeneity within the studies was demonstrated by $\chi^2$ and $I^2$ tests and meta-regression was therefore used to determine the sources of the heterogeneity. This showed that the trend in ORs was inversely correlated with age, which accounted for at least some of the heterogeneity (coefficient = -0.16, $P = 0.042$, adjusted $R^2 = 44.47\%$). These results were consistent with the results of subgroup analysis according to age. The incidence of age-related methylation in most organs was in accordance with the reported incidences of methylation in their malignant counterparts [45]. RUNX3 methylation was reported to occur preferentially in the lower third portion of the stomach in individuals older than 70 years [45]. We found that the ORs for RUNX3 methylation decreased from 15.00 in the younger age group, through 6.31, to 3.75 in the oldest age group. The coefficient for age was calculated to be -0.16 by meta-regression analysis, indicating that the tendency for RUNX3 methylation decreased with advancing age. To the best of our knowledge, the current study is the first to report this finding. However, there was no significant difference in RUNX3 promoter methylation status of cancer tissues between older (more than 60) and younger (less than 60) individuals. This suggests that RUNX3 methylation was not correlated with age in gastric cancer tissue. However, in accordance with the previous study, RUNX3 methylation did decrease

| Table 2 Subgroup analysis |
|---------------------------|
| Group | Cancer M+ | Normal N | Sum M+ | M-H pooled OR | D+L pooled OR | Heterogeneity |
| | | | | OR (95%CI) | OR (95%CI) | $\tau^2$ |
| Total | 475 | 928 | 159 | 812 | 1740 | 5.52(4.30, 7.10) | 13.3 | < 0.0001 | 5.63 | < 0.0001 | 57.91 | 74.1 | < 0.0001 | 0.94 |
| Tissue subgroup | | | | | | |
| Autologous tissue | 362 | 739 | 117 | 728 | 1467 | 7.15(5.36, 9.53) | 13.4 | < 0.0001 | 6.42 | (4.07,10.11) | 8 | < 0.0001 | 24.12 | 50.02 | 0.02 | 0.32 |
| Heterogeneous tissue | 113 | 189 | 42 | 84 | 273 | 5.52(4.30, 7.10) | 2.22 | 0.026 | 4.44 | (0.35,56.70) | 1.15 | 0.251 | 18.69 | 89.3 | < 0.0001 | 4.21 |
| Origin subgroup | | | | | | |
| Japan | 234 | 441 | 89 | 332 | 773 | 3.20(2.30, 4.47) | 6.86 | < 0.0001 | 3.20(1.60,6.39) | 3.29 | 0.001 | 25.03 | 72.0 | 0.001 | 0.7 |
| Euro-America | 65 | 85 | 45 | 85 | 170 | 8.12(2.76, 23.88) | 3.8 | < 0.0001 | 5.15 (0.23,113.17) | 1.04 | 0.299 | 5.95 | 83.2 | 0.015 | 4.14 |
| China | 132 | 249 | 14 | 253 | 502 | 18.44 (10.30, 33.03) | 9.8 | < 0.0001 | 26.19 (8.04,85.33) | 5.42 | < 0.0001 | 5.82 | 48.4 | 0.121 | 0.66 |
| Korea | 44 | 153 | 11 | 142 | 295 | 5.10(2.48, 10.47) | 4.42 | < 0.0001 | 4.96 (2.14,11.47) | 3.74 | < 0.0001 | 1.18 | 15.5 | 0.277 | 0.07 |
| Age subgroup | | | | | | |
| age < 60 | 46 | 114 | 4 | 133 | 247 | 15.25(5.33, 43.61) | 5.08 | < 0.0001 | 15.00 (5.21,43.15) | 5.02 | < 0.0001 | 0.6 | < 0.0001 | 0.437 | < 0.0001 |
| 60≤age < 65 | 276 | 539 | 83 | 465 | 1004 | 7.41(5.15, 10.62) | 10.9 | < 0.0001 | 6.31 (3.19,12.46) | 5.3 | < 0.0001 | 18.88 | 62.9 | 0.009 | 0.54 |
| age ≥65 | 153 | 245 | 72 | 214 | 459 | 2.93(1.98, 4.32) | 5.39 | < 0.0001 | 3.75 (1.29,10.89) | 2.43 | 0.015 | 25.18 | 80.1 | < 0.0001 | 1.31 |

Table 3 Meta-regression

| Sources | Coefficient (95%CI) | t | P | $\tau^2$ | $I^2$ Res (%) | Adjusted $R^2$ (%) |
|---------|---------------------|---|---|--------|-------------|-----------------|
| Sample size | -0.01 (-0.03, 0.01) | -1.04 | 0.314 | 1.07 | 75.33 | -7.96 |
| Year of publication | 0.19 (0.07, 0.46) | 1.54 | 0.145 | 0.90 | 71.95 | 9.9 |
| Proportion of males | -2.91 (-9.67, 3.84) | -0.93 | 0.370 | 1.03 | 75.5 | -3.89 |
| Control type | -1.06 (-2.87, 0.76) | -1.25 | 0.233 | 0.70 | 65.97 | 29.99 |
| Age | -0.16 (-0.31, -0.01) | -2.22 | 0.042 | 0.52 | 63.91 | 44.47 |
| Origin of the patients | -0.57 (-1.16, 0.03) | -2.05 | 0.060 | 0.66 | 66.74 | 33.92 |
with advancing age in normal gastric mucosa [45]. The negative correlation between RUNX3 methylation and age suggests that the influence of RUNX3 methylation on gastric cancer is reduced in older individuals.

Other factors including sample size, year of publication, proportion of males, and the origins of the patients were not identified as sources of heterogeneity by meta-regression analysis.

Meta-analysis of small studies may result in biased results. The funnel plot showed that the standard errors in four of the studies exceeded the 95% confidence limit, and the Egger’s regression line showed that the smaller studies tend to report more positive association of RUNX3 promoter methylation with gastric cancer but was not significant (P = 0.593).

Table 4 Sensitivity analysis

| Study omitted     | Estimate OR | 95% CI       |
|------------------|-------------|--------------|
| Waki(a) (2003)   | 5.40        | 2.90 – 10.06 |
| Waki(b) (2003)   | 5.92        | 3.19 – 10.98 |
| Oshimo (2004)    | 6.55        | 4.12 – 10.43 |
| Nakase (2005)    | 5.74        | 3.09 – 10.66 |
| Homma (2006)     | 6.09        | 3.37 – 11.00 |
| So (2006)        | 6.00        | 3.25 – 11.08 |
| Gargano (2007)   | 5.16        | 2.85 – 9.32  |
| Kitajima (2008)  | 5.74        | 3.03 – 10.86 |
| Li (2008)        | 5.15        | 2.90 – 9.14  |
| Song (2008)      | 5.89        | 3.12 – 11.13 |
| Kim (2009)       | 5.46        | 2.97 – 10.04 |
| Zou (2009)       | 5.08        | 2.89 – 9.93  |
| Hu (2010)        | 5.30        | 2.86 – 9.83  |
| Chen (2010)      | 5.15        | 2.85 – 9.29  |
| Hiraki (2010)    | 5.95        | 3.16 – 11.20 |
| Mikata (2010)    | 5.80        | 3.14 – 10.73 |
| Combined         | 5.63        | 3.15 – 10.06 |

There were no significant differences in RUNX3 methylation in cancer tissues in relation to gender, TNM stage, invasion of tumors into vessels or lymphatic ducts, or tumor stage. Although some studies have reported significant differences in methylation status and protein expression of RUNX3 in relation to tumor invasion depth [46], the overall results of the current study failed to support the existence of such a relationship. Previous studies have also reported increased methylation of RUNX3 in stage I and II gastric cancers, suggesting that the RUNX3 gene contributes to gastric cancer development [38]. However, the results of the current meta-analysis did not support this assumption. Other factors, such as tumor invasion of blood vessels, lymph nodes or lymphatic ducts, and tumor metastases, also demonstrated no relation with RUNX3 methylation.

The aggregated results found that RUNX3 methylation was more frequent in intestinal-type compared with diffuse-type gastric carcinomas, suggesting that inactivation of RUNX3 might play a more significant role in the development of intestinal-type gastric carcinomas.

Analysis of the pooled data also showed that undifferentiated gastric cancers had a higher methylation OR than well-differentiated cancer tissues. This suggests that RUNX3 promoter methylation or down-regulation of the RUNX3 gene may be related to poor prognosis, as suggested in previous studies [47,48].

Conclusions
In conclusion, this meta-analysis of pooled data provides additional evidence to support a strong association between methylation of the RUNX3 promoter and gastric cancer. This association depended on patient origin and the controls used, and further studies are needed to explore these aspects. Younger individuals had higher RUNX3 methylation rates than older individuals. RUNX3 methylation was also associated with histological type and differentiation state of the gastric cancer. However, gender, TNM stage, invasion of tumors into
blood vessels or lymphatic ducts, and tumor stage showed no significant associations with RUNX3 methylation in gastric cancer tissues.

**Abbreviations**

RUNX3: Runt-related transcription factor 3; PEBP2: polyomavirus enhancer binding protein 2; CBF: core binding factors; TGF-β: transforming growth factor-β; LOH: loss of heterozygosity; OR: odds ratio; CI: confidence interval; TMM: tumor node metastasis.

**Acknowledgements**

Our present study was supported by the National Health Key Special Fund (2008201212), the Health Department Fund (2007A093), the Traditional Chinese Medicine Bureau Fund (2007ZJ018), the Natural Science Fund of Zhejiang Province (2012080011, 22080514), and the Key Project of Zhejiang Province (2009C0312-5).

**Author details**

1Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University, School of Medicine, 88 Jiefang Road, Hangzhou, China.
2Department of Orthopaedics, Second Affiliated Hospital (Binjiang Branch), Zhejiang University, School of Medicine, 88 Jiefang Road, Hangzhou, China.
3Department of Pharmacy, Second Affiliated Hospital, Zhejiang University, School of Medicine, 88 Jiefang Road, Hangzhou, China.
4Department of General Surgery, Zhejiang Provincial People’s Hospital, 158 Shantang Road, Hangzhou, China.
5Department of Burns, Second Affiliated Hospital, Zhejiang University, School of Medicine, 88 Jiefang Road, Hangzhou, China.

**Authors’ contributions**

All authors have made substantial contributions to this article: WP, XX, ZY and CH contributed to the conception, design and final approval of the submitted version. WF, XX, ZY and CH contributed to the acquisition and interpretation of data, and drafting of the article. TH, NW and YZ contributed to the acquisition of data and revision of the article. WH, ZM and CZ contributed to the acquisition and revision of the article. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 30 March 2011 **Accepted:** 25 August 2011

Published: 25 August 2011

**References**

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49(1):53-64, 31.
3. Li QL, Ito K, Sakaiya C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HW, Kim JW, Yamamoto H, Yamashita N, Yano T, Ikeda T, Ishida M, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109(1):113-124.
4. Guo WH, Cheng LQ, Ito K, Chen LF, Nakashita H, Tatematsu M, Ito Y: Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 2002, 21(54):8351-8355.
5. Bae SC, Choi JY: Tumor suppressor activity of RUNX3. Oncogene 2004, 23(24):4363-4360.
6. Yamamura Y, Lee WL, Inoue K, Ito H, Ito Y: RUNX3 cooperates with Fox3a to induce apoptosis in gastric cancer cells. J Biol Chem 2006, 281(18):5267-5276.
7. Hanai J, Chen LF, Kanno T, Hatanaka-Fujita N, Kim WY, Guo WH, Inamurah T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawakata M, Miyazono K, Ito Y: Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 1999, 274(44):31577-31582.
8. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang CH, Bhalla KN, Zhu T, Ito Y, Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Research 2006, 66(13):6512-6520.
9. Gao F, Huang CH, Lin M, Wang Z, Shen J, Zhang HY, Jiang L, Chen QM: Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol 2009, 135(5):739-747.
10. Jones PA: The DNA methylation paradox. Trends Genet 1999, 15(1):34-37.
11. Fukamachi H, Ito K: Growth regulation of gastric epithelial cells by Runx3. Oncogene 2004, 23(24):4330-4335.
12. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim U, Shin JH, Han IO, Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004, 23(40):6736-6742.
13. Imamura Y, Hiki B, Kikoe M, Fujiwara M, Kodera Y, Ito K, Nakao A: RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res 2005, 25(4):2657-2660.
14. Oshino Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Ito Y, Chayama K, Yatsu W: Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004, 71(3):137-143.
15. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WM: Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008, 180(3):1141-1145.
16. Hwang KT, Han W, Bae JY, Hwang SE, Shin HJ, Lee JE, Kim SW, Min HJ, Noh DY: Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J Korean Med Sci 2007, 22(Suppl):S24-31.
17. Yanagawa N, Tamura G, Ozumi H, Takahashi N, Shimazaki Y, Motoyama T: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003, 94(7):589-592.
18. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, Jiang L, Chen Q: Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol 2009, 135(5):739-747.
19. Tan JS, Ito H, God BC, Hsieh W, Loh M, Ito Y: Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Res 2006, 26(4B):4287-4292.
20. Levanon D, Brenner O, Otto F, Groner Y: RUNX3 knockouts and stomach cancer. EMBO Rep 2003, 4(6):560-564.
21. Levanon D, Bettoun D, Harms-Cerntu C, Woolf E, Negreneu V, Elam R, Bernstein Y, Goldenberg D, Xiao C, Fleegma S, Brenner O, Otto F, Lev-Tov A, Groner Y: The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 2002, 21(13):3454-3463.
22. Carvalho R, Milne AN, Polak M, Conver WE, Offerhaus GJ, Werstman MA: Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas. Oncogene 2005, 24(50):6252-6259.
23. Nita C, Polycarpou A, Joannidis JP: Meta-analysis of the association of the catepsin D Ala224Val gene polymorphism with the risk of Alzheimer’s disease: a HUge gene-disease association review. Am J Epidemiol 2004, 159(6):527-536.
24. Dersimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
25. Higgins JPT, Green S (editors): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011] The Cochrane Collaboration, 2011 [http://www.cochrane-handbook.org].
26. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 2003, 94(4):360-364.
27. Nakase Y, Sakaiya C, Miyagawa K, Kin S, Fukuda K, Yangaiwa A, Koida K, Morofuji N, Hosokawa Y, Shimomura K, Katsura K, Hagiwara A, Yamagishi H, Ito K, Ito Y: Frequent loss of RUNX3 gene expression in remnant stomach and adjacent mucosa with special reference to topography. Br J Cancer 2005, 92(1):562-569.
28. Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S, Motoyama T: Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci 2006, 97(1):51-56.
29. So K, Tamura G, Honda T, Homma N, Endoh M, Togawa N, Nishizuka S, Motoyama T: Quantitative assessment of RUNX3 methylation in neoplastic and non-neoplastic gastric epithelia using a DNA microarray. Pathol Int 2006, 56(10):571-575.
30. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K: Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol 2007, 42(11):866-873.

31. Gargano G, Calacica D, Corsale S, Agnese V, Intrivici C, Fulvio F, Pantuso G, Cajozzo M, Morello V, Tomasonio RM, Ottini L, Colucci G, Baxan V, Russo A: Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell’Italia Meridionale) prospective study. Ann Oncol 2007, 18(Suppl 6):vi103-109.

32. Fuji S, Ito K, Ito Y, Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008, 283(25):17324-17332.

33. Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y, Miyazaki K: Helicobacter pylori infection is an independent risk factor for RUNX3 methylation in gastric cancer. Oncol Rep 2008, 19(1):197-202.

34. Li LY, Li JK, Shen Y, Yu L, Zhang JH: (Promotor methylation and expression of Runx3 gene in gastric cancer). Zhonghua Wei Chang Wai Ke Za Zhi 2008, 11(4):379-382.

35. Song HJ, Shim KN, Joo YH, Kim SE, Jung SA, Yoo K: Methylation of the Tumor Suppressor Gene RUNX3 in Human Gastric Carcinoma. Gut Liver 2008, 2(2):119-125.

36. Kim JH, Jung EJ, Lee HS, Kim MA, Kim WH: Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma. Oncol Rep 2009, 21(5):1251-1259.

37. Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ: Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol 2009, 40(11):1534-1542.

38. Chen W, Gao N, Shen Y, Cen JH: Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 2010, 25(4):823-831.

39. Hiraki M, Kitajima Y, Sato S, Mitsuno M, Koga Y, Nakamura J, Hashiguchi K, Nozsho H, Miyazaki K: Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer. Ann Surg Oncol 2010, 17(4):1177-1186.

40. Hu SL, Huang DB, Sun YB, Wu L, Xu WP, Yin S, Chen J, Jiang XD, Shen G: Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer. Med Oncol 2010.

41. Mikata R, Fukai K, Imazeki F, Arai M, Fujiwara K, Yonemitsu Y, Zhang K, Nabeya Y, Ochiai T, Yokosuka O: BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. Oncol Rep 2010, 23(6):1701-1708.

42. Brenner O, Levanon D, Negeanu V, Golubkov O, Fainaru O, Woolf E, Groner Y: Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA 2004, 101(45):16016-16021.

43. Ito K, Inoue KI, Bae SC, Ito Y: Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 2009, 28(10):1379-1384.

44. Chuang LSH, Ito Y: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010, 29(18):2605-2615.

45. Waki T, Tamura G, Sato M, Motoyama T: Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003, 22(26):4128-4133.

46. Jung SH, Chung WC, Lee KM, Paik CN, Jung JH, Lee MK, Lee YK, Chung IS: Risk factors in malignant transformation of gastric epithelial neoplasia categorized by the revised Vienna classification: endoscopic, pathological, and immunophenotypic features. Gastro Cancer 2010, 13(2):123-130.

47. Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, Wu TT, Huang S, Xie K: Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 2005, 65(11):4809-4816.

48. Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, Lu PJ, Hsiao M: Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 2009, 16(6):1686-1694.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-230X/11/92/prepub